论文部分内容阅读
我们采用了放免方法测定了30例正常人,30例脑肿瘤患者的血浆和脑脊液中cAMP、cGMP的含量。其中恶性肿瘤6例,良性肿瘤24例。其结果表明,脑肿瘤组血浆和脑脊液cAMP、cGMP的含量较正常对照组明显增高(P<0.005、P<0.001);恶性肿瘤组较良性肿瘤绍高;肿瘤组织的恶性度越高则血浆和脑脊液中cAMP/cGMP的比值就越低(P<0.01、P<0.05)。故我们认为血浆和脑脊液中cAMP、cGMP代谢水平的测定可以作为脑肿瘤病人的早期诊断、肿瘤监视和患者预后的一项参考指标。
We used radioimmunoassay to determine the levels of cAMP and cGMP in plasma and cerebrospinal fluid in 30 normal and 30 brain tumor patients. Including 6 cases of malignant tumors, benign tumors in 24 cases. The results showed that the levels of cAMP and cGMP in plasma and cerebrospinal fluid in brain tumor group were significantly higher than those in normal control group (P <0.005, P <0.001); malignant tumor group was higher than benign tumor; the higher the malignant degree of tumor tissue was, The ratio of cAMP / cGMP in CSF was lower (P <0.01, P <0.05). Therefore, we believe that the determination of cAMP and cGMP metabolism in plasma and cerebrospinal fluid can be used as a reference index for the early diagnosis of brain tumor patients, tumor surveillance and prognosis of patients.